Reassessing antimalarial use in long-term SLE clinical trials - Authors' reply [0.03%]
关于长期狼疮临床试验中抗疟药使用的再评估——作者回复
Vibeke Strand,Kenneth C Kalunian,Kai Wai Lee et al.
Vibeke Strand et al.
The Lancet Rheumatology
The Lancet Rheumatology
Heather Van Epps
Heather Van Epps
Microscopic polyangiitis presenting with retinal frosted branch angiitis [0.03%]
以视网膜树枝状霜斑样血管炎表现为临床首发的微小多血管炎病例报告
Tajamul H Mir,Reem Javeed,Bushra Jabeen et al.
Tajamul H Mir et al.
Jia Li,Zhichun Gu,Hanlin Yin et al.
Jia Li et al.
Neil Basu,Kristian Stefanov
Neil Basu
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study [0.03%]
针对类风湿关节炎TNF抑制治疗临床反应的脑激活预测标志物研究（PreCePra）：一项随机、多中心、双盲、安慰剂对照的Ⅲ期试验
Andreas Hess,Koray Tascilar,Hanna M Schenker et al.
Andreas Hess et al.
Background: Rheumatoid arthritis is an inflammatory disease frequently treated with TNF inhibitors. Little is known about predictors of response to TNF inhibitors. Because clinical response in rheumatoid arthritis is meas...
David Fl Liew,Claire E Owen
David Fl Liew
Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial [0.03%]
复发性多肌炎患者的sarilumab治疗：三期双盲随机对照试验中的患者报告结局指标
Vibeke Strand,Jerome Msihid,Jennifer Sloane et al.
Vibeke Strand et al.
Background: Sarilumab is approved for adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. We aimed to evaluate the effect of saril...